Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | THRB | P10828 | 5/20 | 0.34 |
| ▸ | THRA | P10827 | 4/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | UGT1A1 | P22309 | 1/20 | 0.34 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.34 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 2/20 | 0.33 |
| ▸ | BRD9 | Q9H8M2 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 2/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23168840 | 0.83 | TSHR (0.53) | ALDH1A1CYP2C19LMNAGAAPOLB | |
| SCHEMBL23168750 | 0.83 | MET (0.45) | PTGS2ALDH1A1LMNAMAPTPOLB | |
| SCHEMBL24822268 | 0.82 | PTGS2 (0.40) | PTGS2ALDH1A1CYP2C19LMNACYP1A2 | |
| SCHEMBL23152132 | 0.81 | MAPT (0.38) | PTGS2ALDH1A1CYP2C19LMNACYP1A2 | |
| SCHEMBL24820997 | 0.78 | MAPT (0.38) | MAPTTHRBTHRACYP2C9UGT1A1 | |
| SCHEMBL29488641 | 0.75 | PTGDR2 (0.36) | CYP2C19CYP1A2MAPTCYP2C9CYP3A4 | |
| SCHEMBL24819267 | 0.75 | KMT2A (0.49) | ALDH1A1LMNAMAPTTSHRSMN1; SMN2 | |
| SCHEMBL24821005 | 0.75 | MAPT (0.35) | CYP2C19CYP1A2MAPTCYP2C9CYP3A4 | |
| SCHEMBL23168669 | 0.73 | MAPT (0.44) | PTGS2ALDH1A1LMNAMAPT | |
| SCHEMBL23168782 | 0.73 | FAAH (0.41) | MAPTTHRBTHRACYP2C9UGT1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12617769-B2 | Chemical compound as thyroid hormone beta receptor agonist and use thereof | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2026-05-05 | — | — | US | disclosed |
| US-20220411400-A1 | CHEMICAL COMPOUND AS THYROID HORMONE BETA RECEPTOR AGONIST AND USE THEREOF | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2022-12-29 | — | — | US | disclosed |
| US-20220411400-A1 | CHEMICAL COMPOUND AS THYROID HORMONE BETA RECEPTOR AGONIST AND USE THEREOF | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2022-12-29 | — | — | US | disclosed |
| EP-4036090-A1 | CHEMICAL COMPOUND AS THYROID HORMONE BETA RECEPTOR AGONIST AND USE THEREOF | Sunshine Lake Pharma Co., Ltd. (CN) | 2022-08-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220411400-A1 | CHEMICAL COMPOUND AS THYROID HORMONE BETA RECEPTOR AGONIST AND USE THEREOF | THRB, TSHR, THRA | PTGS2 1229/4885ALDH1A1 1134/4885CYP2C19 630/4885 |
| US-12617769-B2 | Chemical compound as thyroid hormone beta receptor agonist and use thereof | THRB, TSHR, THRA | PTGS2 2614/4885ALDH1A1 1340/4885CYP2C19 1833/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.